---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-010208"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2024-03-18T23:59:59+00:00"
generated_at: "2026-06-04T15:49:42.471958+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Calidi's FY2023 loss widens to $29.2M; cash only $1.9M; capital raise needed for key trials

## Summary
- Net loss for FY2023 was $29.2M ($1.73 per share) vs $25.4M ($2.99 per share) in FY2022.
- Cash and restricted cash totaled $2.1M at Dec 31, 2023, up from $0.6M a year prior but still low.
- Q4 R&D expenses rose to $4.0M (from $2.3M) and G&A to $5.9M (from $2.4M) year-over-year.
- City of Hope received $5.3M CIRM grant for CLD-101 ovarian cancer study; RTNova platform announced.
- Interim Phase 1 data for CLD-101 expected 2Q 2024 'assuming we are successful in raising additional capital.'

## SEC filing metadata
- accession: 0001493152-24-010208
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2024-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315224010208/0001493152-24-010208-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315224010208/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-010208
- JSON: https://secwatch.observer/filing/0001493152-24-010208.json
- Plain text: https://secwatch.observer/filing/0001493152-24-010208.txt

## Key facts
- Earnings Releases
  Calidi Biotherapeutics, Inc. reported financial results for fourth quarter and full fiscal year ended December 31, 2023.
  - Period: fourth quarter and full fiscal year ended December 31, 2023
  - Result: reported results
  source text: On March 15, 2024, Calidi Biotherapeutics, Inc. (the "Company") issued a press release setting forth certain financial and operational information for its fourth fiscal quarter and full fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000149315224010208/0001493152-24-010208-index.htm
- Earnings Releases
  Calidi Biotherapeutics, Inc. reported three months ended December 31, 2023 results: net income net loss of $8.2 million, or $0.23 per share, EPS $0.23 per share.
  - Period: three months ended December 31, 2023
  - Net income: net loss of $8.2 million, or $0.23 per share
  - EPS: $0.23 per share
  - Result: reported results
  source text: The company reported a net loss of $8.2 million, or $0.23 per share, for the three months ended December 31, 2023, compared to a net loss of $7.8 million, or $0.90 per share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000149315224010208/0001493152-24-010208-index.htm
- Earnings Releases
  Calidi Biotherapeutics, Inc. reported year ended December 31, 2023 results: net income net loss of $29.2 million, or $1.73 per share, EPS $1.73 per share.
  - Period: year ended December 31, 2023
  - Net income: net loss of $29.2 million, or $1.73 per share
  - EPS: $1.73 per share
  - Result: reported results
  source text: The company reported a net loss of $29.2 million, or $1.73 per share, for the year ended December 31, 2023, compared to a net loss of $25.4 million, or $2.99 per share, for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000149315224010208/0001493152-24-010208-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.